# AI Proteins

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ai-proteins

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aiproteins.com
- Total disclosed funding: $34M
- Latest round: Series A (Nov 18, 2025)
- Investors on record: 4

## About

Founded in 2021 by Carl Novina, Chris Bahl (CSO), Marc Cohen, and based in Massachusetts, US, AI Proteins, Inc. operates as a biotechnology-based company that uses artificial intelligence to design synthetic proteins to help produce various therapeutic medicines. In November 2025, AI Proteins, Inc. raised USD 22.75 million in series A funding from Mission BioCapital and Sante Ventures, Lightchain Capital and Cobro Ventures. The company will use the funding to accelerate AI-driven design and development of de novo miniprotein medicines and establish a hub-and-spoke model for specialized programs. The company develops novel therapeutics and medicines by designing and engineering synthetic miniproteins from scratch using robotics and the firm's computational protein design. The company will use the November 2025 funding to accelerate AI-driven design and development of de novo miniprotein medicines and establish a hub-and-spoke model for specialized programs.

## Funding rounds

- Series A, Nov 18, 2025, $23M — Sante Ventures, Mission Biocapital, Cobro Ventures, Lightchain Capital
- Seed, Jan 11, 2022, $11M — Cobro Ventures, Lightchain Capital

## Investors

- Cobro Ventures (https://capitalatlas.ai/funds/cobro-ventures) — Seed, Series A
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Seed, Series A
- Sante Ventures (https://capitalatlas.ai/funds/sante-ventures) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A